secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2026-10-06T11:30:06+00:00
Accession:  0001493152-26-045844
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Kairos Pharma reports ENV-105 plus apalutamide median PFS of 17.7 months vs 2 months in Phase 2 mCRPC trial (P=0.0008)
--------------------------------------------------------------------------------

- Interim Phase 2 analysis showed a statistically significant PFS difference for ENV-105 plus apalutamide vs apalutamide alone (median 17.7 vs 2 months; P=0.0008).
- Kairos modified the Phase 2 protocol to enroll patients earlier, after PSA increase on an androgen signaling inhibitor, randomized to enzalutamide alone or with ENV-105.
- The company targets completion of the Phase 2 trial in or before Q4 2027; CEO John Yu called the interim results an important clinical signal for ENV-105.
- Patients were enrolled at Cedars-Sinai Medical Center, City of Hope and Huntsman Cancer Institute at the University of Utah.
- ENV-105 (carotuximab) targets CD105, which Kairos describes as a key driver of resistance and relapse after standard cancer therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/0001493152-26-045844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer